Navamedic recently announced that they have entered into an exclusive distribution agreement with Angelini Pharma for ThermaCare® in the Nordics and the strategically important Dutch market. With the agreement, Navamedic strengthens its position in the Consumer Health segment and enters the important pain category.
ThermaCare® was launched by Procter & Gamble in 2001 and is an advanced pain therapy for back, neck and muscles, classified as a Medical Device class IIa. The therapy is applied as heat wraps which is activated upon contact with air and placed on pain points, exactly where the user needs it. ThermaCare® delivers up to 16 hours of pain relief, 8 hours while used and 8 hours after it has been taken off. The larger adhesive area makes it easy to re-adjust, and the single-use wraps are thin enough to be worn discreetly under clothing.
Angelina Pharma is a part of the Italian Angelini Group and they acquired the ThermaCare® global business rights (excluding North America) from GSK earlier this year. In the distribution agreement now entered into with Angelina Pharma, Navamedic will take over and accelerate marketing, sales and distribution of ThermaCare® in the Nordics and Netherlands from July 2020. The agreement has a duration of eight years, with options to extend.
For further info, please see company press release: http://www.navamedic.com/no/nyheter/2020/03/navamedic-asa-enters-into-distribution-agreement-for-thermacare-with-angelini-pharma/
